Executive Order On Rx Prices Could Direct CMS To Test Value-Based Designs By Waiving Anti-Kickback, Best-Price Rules

President Donald Trump could use an executive order to direct the CMS innovation center to waive rules that would make it easier for drug companies and insurance companies to use value-based contracts, said Paul Howard, director and senior fellow at the Manhattan Institute. Drug industry representatives met with administration officials Friday (June 16) to discuss policies aimed at curbing drug price increases, and drug industry lobbyists said news reports about a soon-to-be-released executive order aimed at encouraging value-based contracts are...